IRD Stock Analysis: Opus Genetics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 370m USD | 12M Return: 321.3% | US67577R1023 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 3.92M
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Opus Genetics, Inc. (NASDAQ: IRD) is a U.S.-based, clinical-stage biopharmaceutical company focused on developing gene therapies for inherited retinal diseases (IRDs) and other ophthalmic disorders. Its lead clinical candidate, OPGx-LCA5, is in a Phase 1/2 trial for LCA5-associated IRD, with OPGx-BEST1 advancing for BEST1-associated retinal disease. The company is also advancing a pipeline of pre-clinical gene therapy programs targeting conditions such as autosomal dominant retinitis pigmentosa, retinal dystrophy, and MERTK- and CNGB1-related IRDs.
Beyond its gene therapy portfolio, Opus is developing Phentolamine Ophthalmic Solution for reversal of mydriasis, presbyopia, and night vision disturbances, as well as APX3330, a small-molecule Ref-1 inhibitor for diabetic retinopathy. The company was founded in 2018, is headquartered in Durham, North Carolina, and was formerly known as Ocuphire Pharma, Inc. before rebranding in November 2020. As a clinical-stage biotech, Opus operates in a capital-intensive sector where revenue is typically limited to collaboration or grant income until products reach commercialization, with value largely tied to pipeline progression and regulatory milestones.
- OPGx-LCA5 Phase 1/2 trial enrollment progresses toward interim data
- Cash burn and small market cap raise near-term dilution risk
- FDA orphan drug designation advances lead IRD gene therapy candidate
| Net Income: -107.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: -1.11 > 0.02 and ΔFCF/TA 30.99 > 1.0 |
| NWC/Revenue: 863.3% < 20% (prev 118.3%; Δ 745.0% < -1%) |
| CFO/TA -0.44 > 3% & CFO -40.7m > Net Income -107.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 12.19 > 1.5 & < 3 |
| Outstanding Shares: last quarter (111.4m) vs 12m ago 75.75% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 14.97% > 50% (prev 39.88%; Δ -24.91% > 0%) |
| Interest Coverage Ratio: -19.11 > 6 (EBIT TTM -50.6m / Interest Expense TTM 2.65m) |
| A: 0.92 (Total Current Assets 92.7m - Total Current Liabilities 7.61m) / Total Assets 93.0m |
| B: -2.82 (Retained Earnings -262.2m / Total Assets 93.0m) |
| C: -0.77 (EBIT TTM -50.6m / Avg Total Assets 65.8m) |
| D: -0.12 (Book Value of Equity -13.0m / Total Liabilities 106.0m) |
| Altman-Z'' = -8.49 = D |
As of September 10, 2026, the stock is trading at USD 5.73 with a total of 53,753,766 shares traded. Over the past week, the price has changed by +49.61%, over one month by +56.56%, over three months by +40.44% and over the past year by +321.32%.
Current recommended Stop Loss: 5.30 (which is 7.5% or 1.3 ATR below the current price).
Opus Genetics has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy IRD.
- StrongBuy: 2
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 10.6 | 85.2% |
P/E Forward = 12.0048
P/S = 37.5631
P/B = 23.8194
Revenue TTM = 9.86m USD
EBIT TTM = -50.6m USD
EBITDA TTM = -50.6m USD
Long Term Debt = 36.2m USD (from longTermDebt, last quarter)
Short Term Debt = unknown (none)
Debt = 36.2m USD (corrected: LT Debt 36.2m + ST Debt none)
Net Debt = 14.3m USD (calculated: Debt 36.2m - CCE 21.9m)
Enterprise Value = 384.5m USD (370.2m + Debt 36.2m - CCE 21.9m)
Interest Coverage Ratio = -19.11 (Ebit TTM -50.6m / Interest Expense TTM 2.65m)
EV/FCF = -3.73x (Enterprise Value 384.5m / FCF TTM -103.1m)
FCF Yield = -26.81% (FCF TTM -103.1m / Enterprise Value 384.5m)
FCF Margin = -1.05k% (FCF TTM -103.1m / Revenue TTM 9.86m)
Net Margin = -1.09k% (Net Income TTM -107.6m / Revenue TTM 9.86m)
Gross Margin = unknown ((Revenue TTM 9.86m - Cost of Revenue TTM 53.0k) / Revenue TTM)
Tobins Q-Ratio = 4.14 (Enterprise Value 384.5m / Total Assets 93.0m)
Interest Expense / Debt = 7.31% (Interest Expense 2.65m / Debt 36.2m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -40.0m (EBIT -50.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 9.77 (Total Current Assets 92.7m / Total Current Liabilities 9.49m)
Debt / Equity = -2.79 (negative equity) (Debt 36.2m / totalStockholderEquity, last quarter -13.0m)
Debt / EBITDA = -0.28 (negative EBITDA) (Net Debt 14.3m / EBITDA -50.6m)
Debt / FCF = -0.14 (negative FCF - burning cash) (Net Debt 14.3m / FCF TTM -103.1m)
Total Stockholder Equity = -9.38m (last 4 quarters mean from totalStockholderEquity)
RoA = -163.5% (out of range, set to none)
RoE = 1.15k% (out of range, set to none) (Net Income TTM -107.6m / Total Stockholder Equity -9.38m)
RoCE = -188.6% (out of range, set to none) (EBIT -50.6m / Capital Employed (Equity -9.38m + L.T.Debt 36.2m))
RoIC = -47.11% (negative operating profit) (NOPAT -40.0m / Invested Capital 84.9m)
WACC = 12.01% (E(370.2m)/V(406.4m) * Re(12.62%) + D(36.2m)/V(406.4m) * Rd(7.31%) * (1-Tc(0.21)))
Discount Rate = 12.62% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 59.83 | Cagr: 95.94%
[DCF] Fair Price = unknown (Cash Flow -103.1m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.02 | # QB: 0
Revenue Correlation: -62.67 | Revenue CAGR: -28.61% | SUE: -0.52 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.15 | Chg30d=+2.92% | Revisions=+17% | Analysts=14
EPS current Year (2026-12-31): EPS=-0.93 | Chg30d=+7.37% | Revisions=+29% | GrowthEPS=-16.0% | GrowthRev=-11.8%
EPS next Year (2027-12-31): EPS=-0.72 | Chg30d=+5.81% | Revisions=-25% | GrowthEPS=+22.5% | GrowthRev=+5.2%
[Analyst] Revisions Ratio: +18% (up=5, down=3)